Zogenix (NASDAQ:ZGNX) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

A number of other brokerages have also issued reports on ZGNX. JMP Securities began coverage on shares of Zogenix in a research note on Monday, November 27th. They set an “outperform” rating and a $56.00 target price for the company. Mizuho reissued a “buy” rating and set a $51.00 target price on shares of Zogenix in a research note on Wednesday, November 8th. Leerink Swann reissued an “outperform” rating and set a $50.00 target price (up from $20.00) on shares of Zogenix in a research note on Monday, October 2nd. ValuEngine raised shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $55.00 target price (up from $26.00) on shares of Zogenix in a research note on Friday, September 29th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Zogenix presently has an average rating of “Buy” and a consensus target price of $42.67.

Shares of Zogenix (NASDAQ:ZGNX) traded up $0.95 on Thursday, hitting $35.70. 460,354 shares of the stock were exchanged, compared to its average volume of 765,831. The stock has a market capitalization of $1,130.00, a price-to-earnings ratio of -8.13 and a beta of 1.96. Zogenix has a 1 year low of $7.70 and a 1 year high of $43.35. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.71 and a quick ratio of 2.71.

In related news, Director Roger Hawley sold 11,797 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $37.02, for a total value of $436,724.94. Following the completion of the sale, the director now directly owns 105,575 shares of the company’s stock, valued at $3,908,386.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Bradley S. Galer acquired 1,346 shares of the stock in a transaction that occurred on Wednesday, December 13th. The stock was acquired at an average cost of $36.59 per share, with a total value of $49,250.14. The disclosure for this purchase can be found here. 6.60% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in ZGNX. J. Goldman & Company purchased a new stake in Zogenix in the third quarter worth about $1,173,000. TFS Capital LLC purchased a new stake in Zogenix in the fourth quarter worth about $4,827,000. Cornerstone Capital Management Holdings LLC. lifted its stake in Zogenix by 400.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 78,456 shares of the company’s stock worth $1,156,000 after acquiring an additional 62,769 shares during the period. J. Goldman & Co LP lifted its stake in Zogenix by 72.1% in the fourth quarter. J. Goldman & Co LP now owns 149,500 shares of the company’s stock worth $2,204,000 after acquiring an additional 62,615 shares during the period. Finally, Pyrrho Capital Management LP lifted its stake in Zogenix by 13.7% in the fourth quarter. Pyrrho Capital Management LP now owns 148,260 shares of the company’s stock worth $2,185,000 after acquiring an additional 17,860 shares during the period. 73.43% of the stock is owned by institutional investors.

WARNING: “Zogenix (ZGNX) Downgraded by BidaskClub” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/11/zogenix-zgnx-downgraded-by-bidaskclub.html.

About Zogenix

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Analyst Recommendations for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.